Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Prograf as secondary intervention vs continuation of cyclosporine in patients at risk for chronic renal allograft failure (CRAF) results in improved renal function, decreased CV risk, and no increased risk for diabetes

Go back to Resources

Prograf as secondary intervention vs continuation of cyclosporine in patients at risk for chronic renal allograft failure (CRAF) results in improved renal function, decreased CV risk, and no increased risk for diabetes

Authors:

Location:

Go back to Resources

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning

Go back to Resources

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Palivizumab prophylaxis of RSV disease: demographic and risk factors results from the 2002-2003 Outcomes Registry

Go back to Resources

Palivizumab prophylaxis of RSV disease: demographic and risk factors results from the 2002-2003 Outcomes Registry

Authors:

Location:

Go back to Resources

Palivizumab prophylaxis of respiratory syncytial virus (RSV) - results from the 2000-2001 Synagis Outcomes Registry

Go back to Resources

Palivizumab prophylaxis of respiratory syncytial virus (RSV) - results from the 2000-2001 Synagis Outcomes Registry

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Ongoing Prospective Multi-Center Safety Study of Subcutaneous Cytoprotectant Amifostine

Go back to Resources

Ongoing Prospective Multi-Center Safety Study of Subcutaneous Cytoprotectant Amifostine

Authors:

Location:

Go back to Resources

Not simply a matter of faulty memory: obstacles to implementing cognitive function ancillary studies in clinical trials with other primary outcomes

Go back to Resources

Not simply a matter of faulty memory: obstacles to implementing cognitive function ancillary studies in clinical trials with other primary outcomes

Authors:

Location:

Go back to Resources

No Changes in Immune Activation Phenotypes, Response to Antigen, or CD8+ T-cell Mediated HIV Suppression in Transplant Recipients Receiving Immunosuppression

Go back to Resources

No Changes in Immune Activation Phenotypes, Response to Antigen, or CD8+ T-cell Mediated HIV Suppression in Transplant Recipients Receiving Immunosuppression

Authors:

Location:

Go back to Resources

No Benefit of 1log T-cell Depletion on Chronic Graft vs Host Disease (cGVHD):Results of a Multi-Center Randomized Trial in 404 Recipients of Unrelated Donor Bone Marrow Transplantation (UBMT)

Go back to Resources

No Benefit of 1log T-cell Depletion on Chronic Graft vs Host Disease (cGVHD):Results of a Multi-Center Randomized Trial in 404 Recipients of Unrelated Donor Bone Marrow Transplantation (UBMT)

Authors:

Location:

Go back to Resources

National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS). AREDS Report No. 10

Go back to Resources

National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS). AREDS Report No. 10

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Mortality in the Age-Related Eye Disease Study: Associations with Lens Opacity and Cataract Surgery

Go back to Resources

Mortality in the Age-Related Eye Disease Study: Associations with Lens Opacity and Cataract Surgery

Authors:

Location:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 137
  • Page 138
  • Page 139
  • Page 140
  • Current page 141
  • Page 142
  • Page 143
  • Page 144
  • Page 145
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions